J Med Chem. 2009 Aug 27;52(16):5176-87. |
Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12.[Pubmed: 19655762] |
Flavaglines constitute a family of natural anticancer compounds.
METHODS AND RESULTS:
We present here 3 (FL3), the first synthetic flavagline that inhibits cell proliferation and viability (IC(50) approximately 1 nM) at lower doses than did the parent compound, racemic Rocaglaol. |
US 20120101153 A1[P]. 2012. |
ROCAGLAOL DERIVATIVES AS CARDIOPROTECTANT AGENTS AND AS ANTINEOPLASTIC AGENTS[Reference: WebLink] |
METHODS AND RESULTS:
The present invention discloses new Rocaglaol derivatives and the use of Rocaglaol derivatives to prevent or to limit the cardiotoxicity of an antineoplastic agent, in particular to prevent or to limit the apoptosis of cardiomyocytes induced by such agent. |
J Nat Prod. 1996 Jul;59(7):650-2. |
Cyclopentabenzofuran lignan protein synthesis inhibitors from Aglaia odorata.[Pubmed: 8759160 ] |
METHODS AND RESULTS:
In the course of screening for Ras function inhibitors, Rocaglaol (1) and the related compounds, the known pyrimidinone (2) and the novel aglaiastatin (3), were isolated from a CHCI3 extract of the leaves of Aglaia odorata.
The structure of 3 was elucidated as a novel cyclopentabenzofuran on the basis of its NMR spectroscopic data and by X-ray crystallographic analysis.
CONCLUSIONS:
These compounds (1-3) were potent inhibitors of the growth of K-ras-NRK cells, with IC50 values of 1-10 ng/mL, and induced normal morphology in K-ras-NRK cells at 10-30 ng/mL. They also specifically inhibited protein synthesis.Aglaiastatin (3) was slightly more potent than 1 and 2 in inhibiting cell growth. Aglaiastatin (3) reduced the amount of Ras, possibly by inhibiting its de novo synthesis. |